Tagged with access,

Sweden Niels Abel Bonde, general manager of Novo Nordisk Sweden, explains the strategic significance of the Swedish market as an innovation-driven environment ideal to run pilot launches and real-world studies. He also breaks down the performance of the affiliate in its main therapeutic areas, as well as the positives and negatives…

China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

Egypt Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He also assesses Egypt’s attractiveness for clinical trials and the initial results of the government’s prioritization of healthcare.   As the…

Egypt Ahmed Mostafa, country manager of Amgen in Egypt and Iran, explains how the affiliate has been growing by providing end-to-end solutions. He also gives his take on the Egyptian government’s prioritization of healthcare and highlights that there are still improvements needed for bringing biosimilars to Egypt.     How would…

Egypt Ayman El Deeb, cluster head of Astellas Egypt, highlights how the Egyptian affiliate of Astellas has been performing since its establishment five years ago. He also discusses the need for better patent protection in the country and explains how Astellas is contributing to the country’s reform of the healthcare system.…

Korea Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country Caretaker) service allows smaller firms to overcome regulatory barriers without having to set up an affiliate years prior to a…

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem.   When I…

France Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic acquisitions and strong productive capabilities. Additionally, he describes the French ecosystem regarding key topics such as big data and market…

France Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.   My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously…

France Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France, and the company’s core philosophy of social responsibility to public health.   We started with contraception and after a few…

USA 59 novel drugs were approved in the USA in 2018, representing a leap from the 46 approved in 2017 and 22 approved in 2016. 19 of the 59 drugs (32 percent) have been designated ‘first-in-class’ and 34 of the 59 drugs (58 percent) were approved to treat rare or “orphan”…